Skip to main content

Newsroom

September 25, 2024

Read Now Button
2024 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter.
August 30, 2024

Alnylam Logo
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).

April 23, 2024

Read Now Button
2024 Spring Newsletter
Catch up on the latest happenings in our spring newsletter.
January 18, 2024

Newsletter logo
2024 Winter Newsletter

Explore the most recent updates in the 2024 Winter Newsletter.